Andrew D Revell1, Luminiţa Ene2, Dan Duiculescu3, Dechao Wang1, Mike Youle4, Anton Pozniak5, Julio Montaner6, Brendan A Larder1. 1. PhD, RDI, London, UK. 2. MD, 'Dr. Victor Babeş' Hospital for Infectious and Tropical Diseases, Bucharest, Romania. 3. MD, PhD, 'Dr. Victor Babeş' Hospital for Infectious and Tropical Diseases, Bucharest, Romania. 4. MD, HIV Training and Resource Initiative, London, UK. 5. MS, Chelsea and Westminster Hospital, London, UK. 6. MD, BC Centre for Excellence in HIV and AIDS, Vancouver, Canada.
Abstract
INTRODUCTION: A major challenge in Romania is the optimisation of antiretroviral therapy for the many HIV-infected adults with, on average, a decade of treatment experience. The RDI has developed computational models that predict virological response to therapy but these require a genotype, which is not routinely available in Romania. Moreover the models, which were trained without any Romanian data, have proved most accurate for patients from the healthcare settings that contributed the training data. Here we develop and test a novel model that does not require a genotype, with test data from Romania. METHODS: A random forest (RF) model was developed to predict the probability of the HIV viral load (VL) being reduced to <50 copies/ml following therapy change. The input variables were baseline VL, CD4 count, treatment history and time to follow-up. The model was developed with 3188 treatment changes episodes (TCEs) from North America, Western Europe and Australia. The model's predictions for 100 independent TCEs from the RDI database were compared to those of a model trained with the same data plus genotypes and then tested using 39 TCEs from Romania in terms of the area under the ROC curve (AUC). RESULTS: When tested with the 100 independent RDI TCEs, the AUC values for the models with and without genotypes were 0.88 and 0.86 respectively. For the 39 Romanian TCEs the AUC was 0.60. However, when 14 cases with viral loads that may have been between 50 and 400 copies were removed, the AUC increased to 0.83. DISCUSSION: Despite having been trained without data from Romania, the model predicted treatment responses in treatment-experienced Romanian patients with clade F virus accurately without the need for a genotype. The results suggest that this approach might be generalisable and useful in helping design optimal salvage regimens for treatment-experienced patients in countries with limited resources where genotyping is not always available.
INTRODUCTION: A major challenge in Romania is the optimisation of antiretroviral therapy for the many HIV-infected adults with, on average, a decade of treatment experience. The RDI has developed computational models that predict virological response to therapy but these require a genotype, which is not routinely available in Romania. Moreover the models, which were trained without any Romanian data, have proved most accurate for patients from the healthcare settings that contributed the training data. Here we develop and test a novel model that does not require a genotype, with test data from Romania. METHODS: A random forest (RF) model was developed to predict the probability of the HIV viral load (VL) being reduced to <50 copies/ml following therapy change. The input variables were baseline VL, CD4 count, treatment history and time to follow-up. The model was developed with 3188 treatment changes episodes (TCEs) from North America, Western Europe and Australia. The model's predictions for 100 independent TCEs from the RDI database were compared to those of a model trained with the same data plus genotypes and then tested using 39 TCEs from Romania in terms of the area under the ROC curve (AUC). RESULTS: When tested with the 100 independent RDI TCEs, the AUC values for the models with and without genotypes were 0.88 and 0.86 respectively. For the 39 Romanian TCEs the AUC was 0.60. However, when 14 cases with viral loads that may have been between 50 and 400 copies were removed, the AUC increased to 0.83. DISCUSSION: Despite having been trained without data from Romania, the model predicted treatment responses in treatment-experienced Romanian patients with clade F virus accurately without the need for a genotype. The results suggest that this approach might be generalisable and useful in helping design optimal salvage regimens for treatment-experienced patients in countries with limited resources where genotyping is not always available.
Authors: Brendan Larder; Dechao Wang; Andrew Revell; Julio Montaner; Richard Harrigan; Frank De Wolf; Joep Lange; Scott Wegner; Lidia Ruiz; Maria Jésus Pérez-Elías; Sean Emery; Jose Gatell; Antonella D'Arminio Monforte; Carlo Torti; Maurizio Zazzi; Clifford Lane Journal: Antivir Ther Date: 2007
Authors: Dechao Wang; Brendan Larder; Andrew Revell; Julio Montaner; Richard Harrigan; Frank De Wolf; Joep Lange; Scott Wegner; Lidia Ruiz; María Jésus Pérez-Elías; Sean Emery; Jose Gatell; Antonella D'Arminio Monforte; Carlo Torti; Maurizio Zazzi; Clifford Lane Journal: Artif Intell Med Date: 2009-06-12 Impact factor: 5.326
Authors: Andrew D Revell; Dechao Wang; Mark A Boyd; Sean Emery; Anton L Pozniak; Frank De Wolf; Richard Harrigan; Julio S G Montaner; Clifford Lane; Brendan A Larder Journal: AIDS Date: 2011-09-24 Impact factor: 4.177
Authors: Andrea De Luca; Antonella Cingolani; Simona Di Giambenedetto; Maria Paola Trotta; Francesco Baldini; Maria Gabriella Rizzo; Ada Bertoli; Giuseppina Liuzzi; Pasquale Narciso; Rita Murri; Adriana Ammassari; Carlo Federico Perno; Andrea Antinori Journal: J Infect Dis Date: 2003-05-22 Impact factor: 5.226
Authors: Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Dineke Frentz; Charles A B Boucher; Matthias Assel; Andrea De Luca; Massimiliano Fabbiani; Francesca Incardona; Pieter Libin; Nino Manca; Viktor Müller; Breanndán O Nualláin; Roger Paredes; Mattia Prosperi; Eugenia Quiros-Roldan; Lidia Ruiz; Peter M A Sloot; Carlo Torti; Anne-Mieke Vandamme; Kristel Van Laethem; Maurizio Zazzi; David A M C van de Vijver Journal: PLoS One Date: 2010-07-09 Impact factor: 3.240
Authors: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman Journal: Clin Infect Dis Date: 2008-07-15 Impact factor: 9.079
Authors: Andrew D Revell; Gerardo Alvarez-Uria; Dechao Wang; Anton Pozniak; Julio S Montaner; H Clifford Lane; Brendan A Larder Journal: Biomed Res Int Date: 2013-09-24 Impact factor: 3.411
Authors: Kuteesa R Bisaso; Susan A Karungi; Agnes Kiragga; Jackson K Mukonzo; Barbara Castelnuovo Journal: BMC Med Inform Decis Mak Date: 2018-09-04 Impact factor: 2.796